摘要
目的：探讨信必可联合噻托溴铵治疗重度稳定期慢性阻塞性肺疾病的临床疗效。方法选取2014年2月~2015年4月重庆市璧山区人民医院呼吸内科收治的98例重度稳定期慢性阻塞性肺疾病患者为研究对象，将患者随机分为观察组和对照组，每组49例，对照组予常规治疗和信必可治疗，观察组在对照组的基础上予噻托溴铵治疗，治疗3个月后，比较两组患者临床疗效、第一秒用力呼气量（FEV1）、第一秒用力呼气量占用力肺活量百分比（FEV1/ FVC）以及血气分析。结果观察组总有效率为83.67%，对照组总有效率为65.31%，比较差异有统计学意义（P〈0.05）；两组治疗后 FEV1、FEV1/ FVC 以及血气分析均较治疗前改善，但观察组改善的程度比对照组更为明显，差异有统计学意义（P〈0.001）。结论信必可联合噻托溴铵治疗重度稳定期慢性阻塞性肺疾病的临床疗效较为显著，能够改善患者动脉血气和肺功能，值得临床推广应用。
Objective To investigate the clinical efficacy of symbicort combined with tiotrpium bromide in the treatment of severe chronic obstructive pulmonary diseases（COPD）in stable phase.Methods 98 patients with COPD in stable phase admitted to People’s Hospital of Bishan District from February,2014 to April,2015 were randomly divided into observation group and control group,with 49 cases in each.The control group were treated with routine treatment and symbicort,while the observation group were added thiazide tiotropium on the basis of the the control group.After 3 months of treatment,clinical curative effect,forced expiratory volume in the first second（FEV1）,FEV1/ FVC（forced vital capacity）and blood gas analysis were compared between the two groups. Results The total effective rate was 83. 67% in the observation group,and was 65. 31% in the control group,so difference was statistically significant（P〈0.05）.The clinical curative effect,FEV1,FEV1/FVC and blood gas analysis of both groups improved after treatment,but the improvement in the observation group was more obvious than that in the control group,so differences were all statistically significant（P〈0.001）.Conclusion Symbicort combined with tiotrpium bromide has obvious clinical efficacy in the treatment of COPD in stable phase,it can significantly improve the arterial blood gas and pulmonary function.Thus,it is worthy of being popularized and applied in clinical practice.
出处
《右江医学》
2016年第3期295-298,共4页
Chinese Youjiang Medical Journal
